DOCSLIB.ORG

Position Paper on MRONJ

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Position Paper on MRONJ saving faces|changing lives® Position Paper American Association of Oral and Maxillofacial Surgeons Medication-Related Osteonecrosis of the Jaw—2014 Update Special Committee on Medication- Introduction Related Osteonecrosis of the Jaws: The Special Committee recommends changing the Salvatore L. Ruggiero, DMD, MD, Clinical nomenclature of bisphosphonate-related osteonecrosis of Professor, Division of Oral and Maxillofacial the jaw (BRONJ). The Special Committee favors the term Surgery, Stony Brook School of Dental Medicine, medication-related osteonecrosis of the jaw (MRONJ). Hofstra North Shore-LIJ School of Medicine, The change is justified to accommodate the growing New York Center for Orthognathic and Maxillo- number of osteonecrosis cases involving the maxilla and facial Surgery, Lake Success, NY mandible associated with other antiresorptive (denosumab) and antiangiogenic therapies. Thomas B. Dodson, DMD, MPH, Professor and Chair, Associate Dean for Hospital Affairs, MRONJ adversely affects the quality of life, produc- University of Washington School of Dentistry, ing significant morbidity. Strategies for management of Department of Oral and Maxillofacial Surgery, patients with, or at risk for, MRONJ were set forth in the Seattle, WA American Association of Oral and Maxillofacial Sur- geons (AAOMS) updated Position Paper on Bisphospho- John Fantasia, DDS, Chief, Division of Oral nate-Related Osteonecrosis of the Jaws and approved by Pathology, Hofstra North Shore-LIJ School of the Board of Trustees in 2009.1 The Position Paper was Medicine , New Hyde Park, NY developed by a Special Committee appointed by the Board Reginald Goodday, Professor, Department of Oral and composed of clinicians with extensive experience in and Maxillofacial Sciences, Dalhousie University, caring for these patients and basic science researchers. The Halifax, NS knowledge base and experience in addressing MRONJ has expanded, necessitating modifications and refinements Tara Aghaloo DDS, MD, PhD, Associate Pro- to the previous Position Paper. This Special Committee fessor, Oral and Maxillofacial Surgery, Assistant met in September 2013 to appraise the current literature Dean for Clinical Research, UCLA School of and revise the guidelines as indicated to reflect current Dentistry, Los Angeles, CA knowledge in this field. This update contains revisions to diagnosis, staging, and management strategies, and high- Bhoomi Mehrotra, MD, Director, Cancer Institute lights current research status. AAOMS considers it vitally at St. Francis Hospital, Roslyn, NY important that this information be disseminated to other Felice O’Ryan, DDS, Division of Maxillofacial relevant health care professionals and organizations. Surgery, Kaiser Permanente Oakland Medical Purpose Center, Oakland, CA The purpose of this updated position paper is to provide: 1. Risk estimates of developing MRONJ 2. Comparisons of the risks and benefits of medications related to osteonecrosis of the jaw (ONJ) in order to facilitate medical decision-making for the treating physician, dentist, dental specialist, and patients 3. Guidance to clinicians regarding: PAGE 1 Medication-Related Osteonecrosis of the Jaw – 2014 Update a. the differential diagnosis of MRONJ in patients with a history of exposure to antiresorptive and/or antiangiogenic agents Position Paper b. MRONJ prevention measures and management strategies for patients with MRONJ based on the disease stage Background ecules disrupting the angiogenesis-signaling cascade. These novel medications have demonstrated efficacy in the Antiresorptive medications treatment of gastrointestinal tumors, renal cell carcinomas, Intravenous (IV) bisphosphonates (BPs) are antiresorp- neuroendocrine tumors and others. tive medications used to manage cancer-related conditions Risks of jaw necrosis related to antiresorptive therapy including hypercalcemia of malignancy, skeletal-related events (SRE) associated with bone metastases in the con- Oral and maxillofacial surgeons first recognized and text of solid tumors such as breast cancer, prostate cancer reported cases of non-healing exposed bone in the max- and lung cancers, and for management of lytic lesions in illofacial region in patients treated with IV bisphospho- the setting of multiple myeloma.2-13 While the potential nates.24,25 In September 2004, Novartis, the manufacturer for bisphosphonates to improve cancer-specific survival of the IV bisphosphonates pamidronate (Aredia®) and remains controversial, these medications have had a signif- zoledronic acid (Zometa®), notified healthcare profession- icant positive effect on the quality of life for patients with als of additions to the labeling of these products, which advanced cancer involving the skeleton. provided cautionary language related to the development of osteonecrosis of the jaws.26 This was followed in 2005 IV BPs, ie once yearly infusion of zolendronate (Reclast®) by a broader drug class warning of this complication for all and a parenteral formulation of ibandronate (Boniva®) bisphosphonates including the oral preparations.27,28 More administered every three months, have FDA approval for recently, other antiresorptive agents and novel anti-cancer 14 management of osteoporosis. drugs have been linked to the development of jaw necrosis Oral bisphosphonates are approved for treatment of (Appendix I, II). osteoporosis and are frequently used to treat osteopenia MRONJ Case Definition as well.15 They are also used for a variety of less common conditions such as Paget’s disease of bone, and osteogen- In order to distinguish MRONJ from other delayed healing esis imperfecta.16,17 The most common use, however, is for conditions and address evolving clinical observations and osteopenia and osteoporosis.18,19 concerns about under-reporting of disease, the working definition of MRONJ has been modified from the 2009 RANK ligand inhibitor (denosumab) is an antiresorptive AAOMS Position Paper:1 agent that exists as a fully humanized antibody against RANK ligand (RANK-L) and inhibits osteoclast func- Patients may be considered to have MRONJ if all tion and associated bone resorption. When denosumab of the following characteristics are present: (Prolia®) is administered subcutaneously every 6 months 1. Current or previous treatment with antire- there is a reduction in the risk of vertebral, non-vertebral, sorptive or antiangiogenic agents; and hip fractures in osteoporotic patients.20,21 Denosumab (Xgeva®) is also effective in reducing SRE related to met- 2. Exposed bone or bone that can be probed astatic bone disease from solid tumors when administered through an intraoral or extraoral fistula(e) in 22,23 monthly. Denosumab therapy is not indicated for the the maxillofacial region that has persisted for treatment of multiple myeloma. Interestingly, in contrast more than eight weeks; and to bisphosphonates, RANK ligand inhibitors do not bind to bone and their effects on bone remodeling are mostly 3. No history of radiation therapy to the jaws or diminished within 6 months of treatment cessation. obvious metastatic disease to the jaws. Antiangiogenic medications It is important to understand that patients at risk for or with established MRONJ can also present with other com- Angiogenesis inhibitors interfere with the formation of mon clinical conditions not to be confused with MRONJ. new blood vessels by binding to various signaling mol- PAGE 2 Medication-Related Osteonecrosis of the Jaw – 2014 Update Commonly misdiagnosed conditions may include, but are not limited to: alveolar osteitis, sinusitis, gingivitis/ periodontitis, caries, periapical pathology, fibro-osseous Position Paper lesion, sarcoma, chronic sclerosing osteomyelitis, and TMJ disorders. It is also important to remember that ONJ occurs in patients not exposed to antiresorptive or antiangiogenic agents. infection.53-55 Although tooth extraction was performed Pathophysiology in most of the initial reported cases of ONJ, these Although the first MRONJ case was reported over a de- teeth commonly had existing periodontal or periapical 1,56-59 cade ago, the pathophysiology of the disease has not been disease. From these clinical studies, several animal fully elucidated.24,25 A source of great debate among clini- models have been developed to demonstrate that cians and researchers are the potential mechanisms under- both inflammation or bacterial infection and systemic 46,60-64 lying MRONJ pathophysiology.29-32 Proposed hypotheses antiresorptives are sufficient to induce ONJ. that attempt to explain the unique localization of MRONJ Inflammation or infection has long been considered an exclusively to the jaws include altered bone remodel- important component of ONJ. Early studies identified ing or oversuppression of bone resorption, angiogenesis bacteria, especially Actinomyces species, in biopsied inhibition, constant microtrauma, suppression of innate or specimens of necrotic bone removed in patients with acquired immunity, vitamin D deficiency, soft tissue BP ONJ.65 The presence of bacteria has prompted studies toxicity, and inflammation or infection.29,33-40 to evaluate the possibility of a complex biofilm on exposed bone.66 These studies have identified bacteria A. Inhibition of osteoclastic bone resorption and in combination with fungi and viruses, which may remodeling require more sophisticated therapies to combat the Bisphosphonates (BP), and other antiresorptives multiorganism ONJ-associated biofilm.67-70 such as denosumab, inhibit osteoclast differentiation and function, and increase
Load more

Recommended publications
  • Related Osteonecrosis of the Jaw in Patients with Sjögren's Syndrome
    Open access Research BMJ Open: first published as 10.1136/bmjopen-2018-024655 on 13 February 2019. Downloaded from Increased risk of bisphosphonate- related osteonecrosis of the jaw in patients with Sjögren’s syndrome: nationwide population-based cohort study Min-Tser Liao,1,2 Wu-Chien Chien,3,4,5 Jen-Chun Wang,6 Chi-Hsiang Chung,3,4,7 Shi-Jye Chu,8 Shih-Hung Tsai6,9 To cite: Liao M-T, Chien W-C, ABSTRACT Strengths and limitations of this study Wang J-C, et al. Increased Objective The aim of this study was to explore whether risk of bisphosphonate- patients with Sjögren’s syndrome (SS) were susceptible ► The strength of our study is its population-based related osteonecrosis of to bisphosphonate (BP)-related osteonecrosis of the jaw the jaw in patients with cohort design with a large number of patients and (BRONJ) after tooth extraction in the entire population of Sjögren’s syndrome: long-term follow-up, which aims to evaluate the Taiwan. nationwide population-based association between Sjögren’s syndrome and os- Design A nationwide population-based retrospective cohort study. BMJ Open teonecrosis of the jaw (ONJ) after tooth extraction. 2019;9:e024655. doi:10.1136/ cohort study. ► The National Health Insurance Research Database Setting Data were extracted from Taiwan’s National bmjopen-2018-024655 registry could not provide detailed information re- Health Insurance Research Database (NHIRD). Prepublication history and garding laboratory results, family histories and ► Methodology Medical conditions for both the study and additional material for this health-related lifestyle factors. control group were categorised using the International paper are available online.
    [Show full text]
  • STIM1 Controls Calcineurin/Akt/Mtor/NFATC2‑Mediated Osteoclastogenesis Induced by RANKL/M‑CSF
    736 EXPERIMENTAL AND THERAPEUTIC MEDICINE 20: 736-747, 2020 STIM1 controls calcineurin/Akt/mTOR/NFATC2‑mediated osteoclastogenesis induced by RANKL/M‑CSF YANJIAO HUANG1, QIANG LI2, ZUNYONG FENG3 and LANRONG ZHENG1 Departments of 1Pathological Anatomy, 2Anatomy and 3Forensic Medicine, Wannan Medical College, Wuhu, Anhui 241002, P.R. China Received October 15, 2018; Accepted June 20, 2019 DOI: 10.3892/etm.2020.8774 Abstract. Store-operated Ca2+ entry (SOCE) is the stable (p.E136X, p.R429C) or constitutively activated (p.R304W) calcium channel influx in most cells. It consists of the SOCE, failed to respond to RANKL/M-CSF-mediated induc- cytoplasmic ion channel ORAI and endoplasmic reticulum tion of normal osteoclastogenesis. In addition, activation of the receptor stromal interaction molecule 1 (STIM1). Abolition calcineurin/Akt/mTOR/NFATC2 signalling cascade induced of SOCE function due to ORAI1 and STIM1 gene defects by RANKL/M-CSF was abnormal in the BMDMs with may cause non-perspiration, ectoderm dysplasia and STIM1 mutants compared with that in BMDMs from healthy skeletal malformations with severe combined immunodefi- subjects. In addition, overexpression of wild-type STIM1 ciency (CID). Calcineurin/mammalian target of rapamycin restored SOCE in p.R429C- and p.E136X-mutant BMDMs, but (mTOR)/nuclear factor of activated T cells 2 (NFATC2) is not in p.R304W-mutant BMDMs. Of note, calcineurin, cyclo- an important signalling cascade for osteoclast development. sporin A, mTOR inhibitor rapamycin and NFATC2‑specific Calcineurin is activated by Ca2+ via SOCE during osteoclas- small interfering RNA restored the function of SOCE in togenesis, which is induced by receptor activator of NF-κB p.R304W-mutant BMDMs.
    [Show full text]
  • Hypophosphatasia Could Explain Some Atypical Femur Fractures
    Hypophosphatasia Could Explain Some Atypical Femur Fractures What we know Hypophosphatasia (HPP) is a rare genetic disease that affects the development of bones and teeth in children (Whyte 1985). HPP is caused by the absence or reduced amount of an enzyme called tissue-nonspecific alkaline phosphatase (TAP), also called bone-specific alkaline phosphatase (BSAP). The absence of TAP raises the level of inorganic pyrophosphate (Pi), which prevents calcium and phosphate from creating strong, mineralized bone. Without TAP, bones can become weak. In its severe form, HPP is fatal and happens in 1/100,000 births. Because HPP is genetic, it can appear in adults as well. A recent study has identified a milder, more common form of HPP that occurs in 4 of 1000 adults (Dahir 2018). This form of HPP is usually seen in early middle aged adults who have low bone density and sometimes have stress fractures in the feet or thigh bone. Sometimes these patients lose their baby teeth early, but not always. HPP is diagnosed by measuring blood levels of TAP and vitamin B6. An elevated vitamin B6 level [serum pyridoxal 5-phosphate (PLP)] (Whyte 1985) in a patient with a TAP level ≤40 or in the low end of normal can be diagnosed with HPP. Almost half of the adult patients with HPP in the large study had TAP >40, but in the lower end of the normal range (Dahir 2018). The connection between hypophosphatasia and osteoporosis Some people who have stress fractures get a bone density test and are treated with an osteoporosis medicine if their bone density results are low.
    [Show full text]
  • • Acute Pericoronitis • End-Stage Renal Disease • Acute Infectious Stomatitis an Acute Apical Abscess Should Not Be a Contraindication to Extraction
    • acute pericoronitis • end-stage renal disease • acute infectious stomatitis An acute apical abscess should not be a contraindication to extraction. It has been shown that these infections can resolve very quickly when the affected tooth is removed. However, it may be diffi - cult to extract such a tooth, either because the patient is unable to open sufficiently wide enough or because adequate local anesthesia cannot be obtained. There are few true contraindications to the extraction of teeth. Note: In some instances, the pa - tients’ health may be so compromised that they cannot withstand the surgical procedure. Examples of contraindications include: • End-stage renal disease • Severe uncontrolled metabolic diseases (i.e., uncontrolled diabetes mellitus) • Advanced cardiac conditions (unstable angina) • Patients with leukemia and lymphoma should be treated before extraction of teeth • Patients with hemophilia or platelet disorders should be treated before extraction of teeth • Patients with a history of head and neck cancer need to be treated with care because even minor surgery can lead to osteoradionecrosis. Note: These patients are often treated with hyperbaric oxygen therapy prior to (20 sessions) and following extractions (10 sessions). • Pericoronitis: infection of the soft tissues around a partially erupted mandibular third molar Note: This infection should be treated prior to removal of the maxillary third molar. • Acute infectious stomatitis and malignant disease are relative contraindications • Treatment with IV bisphosphonates increases the risk of osteonecrosis of the jaw Note: Causes of excessive bleeding after dental extractions include: injury to the inferior alveolar artery during extraction of a mandibular tooth (usually the third molar), a muscular arteriolar bleed from a flap procedure, or bleeding related to the patient’s history (i.e., patients who are on warfarin or drugs for platelet inhibition, patients who have hemophilia or von Willebrand disease, or who have chronic liver insufficiency)..
    [Show full text]
  • A Novel Germline Mutation of ADA2 Gene In
    International Journal of Molecular Sciences Case Report A Novel Germline Mutation of ADA2 Gene in Two “Discordant” Homozygous Female Twins Affected by Adenosine Deaminase 2 Deficiency: Description of the Bone-Related Phenotype Silvia Vai 1,†, Erika Marin 1,† , Roberta Cosso 2 , Francesco Saettini 3, Sonia Bonanomi 3, Alessandro Cattoni 3, Iacopo Chiodini 1,4 , Luca Persani 1,4 and Alberto Falchetti 1,2,* 1 Department of Endocrine and Metabolic Diseases, IRCCS, Istituto Auxologico Italiano, 20145 Milan, Italy; [email protected] (S.V.); [email protected] (E.M.); [email protected] (I.C.); [email protected] (L.P.) 2 IRCCS, Istituto Auxologico Italiano, San Giuseppe Hospital, 28824 Verbania, Italy; [email protected] 3 Department of Pediatrics, Università degli Studi di Milano-Bicocca, Fondazione MBBM, San Gerardo Hospital, 20100 Monza, Italy; [email protected] (F.S.); [email protected] (S.B.); [email protected] (A.C.) 4 Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20122 Milan, Italy * Correspondence: [email protected] † These authors equally contributed to this paper. Abstract: Adenosine Deaminase 2 Deficiency (DADA2) syndrome is a rare monogenic disorder preva- lently linked to recessive inherited loss of function mutations in the ADA2/CECR1 gene. It consists Citation: Vai, S.; Marin, E.; Cosso, R.; of an immune systemic disease including autoinflammatory vasculopathies, with a frequent onset Saettini, F.; Bonanomi, S.; Cattoni, A.; at
    [Show full text]
  • Denosumab and Anti-Angiogenetic Drug-Related Osteonecrosis of the Jaw: an Uncommon but Potentially Severe Disease
    ANTICANCER RESEARCH 33: 1793-1798 (2013) Denosumab and Anti-angiogenetic Drug-related Osteonecrosis of the Jaw: An Uncommon but Potentially Severe Disease STEFANO SIVOLELLA1, FRANCO LUMACHI2, EDOARDO STELLINI1 and LORENZO FAVERO1 Departments of 1Neurosciences, Section of Dentistry and 2Surgery, Oncology and Gastroenterology, University of Padua, School of Medicine, Padova, Italy Abstract. Osteonecrosis of the jaw (ONJ) is a rare but bone exposure in the oral cavity (1). Experimental radio-ONJ serious lesion of the jaw characterized by exposed necrotic was first reported in the 1960s and better-described by Zach bone and is related to several drugs usually used for treating et al. (2, 3). Currently, ONJ may represent a serious problem patients with advanced malignancies. Common therapies in patients irradiated for head and neck carcinomas, but may inducing ONJ are nitrogen-containing bisphosphonates (BPs), also be an uncommon complication of cancer chemotherapy the human monoclonal antibody to the receptor activator of (4, 5). Other causes of ONJ are local malignancy, periodontal nuclear factor-kappa B ligand denosumab and some anti- disease, trauma, and long-term glucocorticoid or angiogenic drugs, alone or in combination with BPs. The real bisphosphonate (BP) therapy (6). ONJ is a potentially incidence of ONJ is unknown. Several cases of ONJ in patients debilitating disease, which occurs in approximately 5% of with cancer who underwent denosumab therapy have been patients with myeloma or bone metastases from breast cancer reported and it seems that the overall incidence of denosumab- (BC) or prostate cancer receiving high-dose intravenous BPs related ONJ is similar to that for BP-related in this (7).
    [Show full text]
  • Bob Dylan Performs “It's Alright, Ma (I'm Only Bleeding),” 1964–2009
    Volume 19, Number 4, December 2013 Copyright © 2013 Society for Music Theory A Foreign Sound to Your Ear: Bob Dylan Performs “It’s Alright, Ma (I’m Only Bleeding),” 1964–2009 * Steven Rings NOTE: The examples for the (text-only) PDF version of this item are available online at: http://www.mtosmt.org/issues/mto.13.19.4/mto.13.19.4.rings.php KEYWORDS: Bob Dylan, performance, analysis, genre, improvisation, voice, schema, code ABSTRACT: This article presents a “longitudinal” study of Bob Dylan’s performances of the song “It’s Alright, Ma (I’m Only Bleeding)” over a 45-year period, from 1964 until 2009. The song makes for a vivid case study in Dylanesque reinvention: over nearly 800 performances, Dylan has played it solo and with a band (acoustic and electric); in five different keys; in diverse meters and tempos; and in arrangements that index a dizzying array of genres (folk, blues, country, rockabilly, soul, arena rock, etc.). This is to say nothing of the countless performative inflections in each evening’s rendering, especially in Dylan’s singing, which varies widely as regards phrasing, rhythm, pitch, articulation, and timbre. How can music theorists engage analytically with such a moving target, and what insights into Dylan’s music and its meanings might such a study reveal? The present article proposes one set of answers to these questions. First, by deploying a range of analytical techniques—from spectrographic analysis to schema theory—it demonstrates that the analytical challenges raised by Dylan’s performances are not as insurmountable as they might at first appear, especially when approached with a strategic and flexible methodological pluralism.
    [Show full text]
  • Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: an Overview
    Journal of Clinical Medicine Review Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview Yoshiya Tanaka The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1, Iseigaoka, Kitakyushu 807-8555, Japan; [email protected]; Tel.: +81-93-603-1611; Fax: +81-93-691-7580 Abstract: In rheumatoid arthritis, a representative systemic autoimmune disease, immune abnor- mality and accompanying persistent synovitis cause bone and cartilage destruction and systemic osteoporosis. Biologics targeting tumor necrosis factor, which plays a central role in the inflammatory process, and Janus kinase inhibitors have been introduced in the treatment of rheumatoid arthritis, making clinical remission a realistic treatment goal. These drugs can prevent structural damage to bone and cartilage. In addition, osteoporosis, caused by factors such as menopause, aging, immobility, and glucocorticoid use, can be treated with bisphosphonates and the anti-receptor activator of the nuclear factor-κB ligand antibody. An imbalance in the immune system in rheumatoid arthritis induces an imbalance in bone metabolism. However, osteoporosis and bone and cartilage destruction occur through totally different mechanisms. Understanding the mechanisms underlying osteo- porosis and joint destruction in rheumatoid arthritis leads to improved care and the development of new treatments. Keywords: rheumatoid arthritis; osteoporosis; joint destruction; DMARD; biologics Citation: Tanaka, Y. Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. J. Clin. Med. 2021, 10, 1. Introduction 1241. https://doi.org/10.3390/ Rheumatoid arthritis is a systemic autoimmune disease characterized by inflammatory jcm10061241 polyarthritis. It occurs commonly in women in their 30s to 60s, and often causes organ disorders.
    [Show full text]
  • RESERVE STUDY GUIDELINES for Homeowner Association Budgets
    State of California Department of Real Estate RESERVE STUDY GUIDELINES for Homeowner Association Budgets August 2010 State of California Department of Real Estate RESERVE STUDY GUIDELINES for Homeowner Association Budgets August 2010 This independent research report was developed under contract for the California Department of Real Estate by Eva Eagle, Ph.D., and Susan Stoddard, Ph.D., AICP, Institute for the Study of Family, Work and Community and David H. Levy, M.B.A., C.P.A. Janet Andrews, MBA, was responsible for the original design, layout, and typography. The Department of Real Estate revised this publication in August 2010. It includes updates by Roy Helsing PRA, RS to insure it aligns with current California Law and the guidelines of the Association of Professional Reserve Preparers (APRA) and the Community Associations Institute (CAI).,” The report does not necessarily reflect the position of the Administration of the State of California. NOTE: Before a homeowners’ association decides to prepare its own Reserve Study, it should consider seeking professional advice on that issue. There are issues concerning volunteer board member indemnification, reliance on expert advice, and other factors that should be considered in that decision. The goal of this manual is to help the reader better understand Reserve Studies. It is not the intent of this manual to define the “standard of care” for Reserve Studies or to interpret the California Civil Code. Department of Real Estate . Publications . 2201 Broadway . Sacramento, CA 95818 . Web
    [Show full text]
  • Paracrine and Endocrine Actions of Bone—The Functions of Secretory
    Bone Research www.nature.com/boneres REVIEW ARTICLE OPEN Paracrine and endocrine actions of bone—the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts Yujiao Han1, Xiuling You1, Wenhui Xing1, Zhong Zhang1 and Weiguo Zou 1 The skeleton is a dynamic organ that is constantly remodeled. Proteins secreted from bone cells, namely osteoblasts, osteocytes, and osteoclasts exert regulation on osteoblastogenesis, osteclastogenesis, and angiogenesis in a paracrine manner. Osteoblasts secrete a range of different molecules including RANKL/OPG, M-CSF, SEMA3A, WNT5A, and WNT16 that regulate osteoclastogenesis. Osteoblasts also produce VEGFA that stimulates osteoblastogenesis and angiogenesis. Osteocytes produce sclerostin (SOST) that inhibits osteoblast differentiation and promotes osteoclast differentiation. Osteoclasts secrete factors including BMP6, CTHRC1, EFNB2, S1P, WNT10B, SEMA4D, and CT-1 that act on osteoblasts and osteocytes, and thereby influenceaA osteogenesis. Osteoclast precursors produce the angiogenic factor PDGF-BB to promote the formation of Type H vessels, which then stimulate osteoblastogenesis. Besides, the evidences over the past decades show that at least three hormones or “osteokines” from bone cells have endocrine functions. FGF23 is produced by osteoblasts and osteocytes and can regulate phosphate metabolism. Osteocalcin (OCN) secreted by osteoblasts regulates systemic glucose and energy metabolism, reproduction, and cognition. Lipocalin-2 (LCN2) is secreted by osteoblasts and can influence energy metabolism by suppressing appetite in the brain. We review the recent progresses in the paracrine and endocrine functions of the secretory proteins of osteoblasts, osteocytes, and osteoclasts, revealing connections of the skeleton with other tissues and providing added insights into the pathogenesis of degenerative diseases affecting multiple organs and the drug discovery process.
    [Show full text]
  • Overuse Injuries in Sport: a Comprehensive Overview R
    Aicale et al. Journal of Orthopaedic Surgery and Research (2018) 13:309 https://doi.org/10.1186/s13018-018-1017-5 REVIEW Open Access Overuse injuries in sport: a comprehensive overview R. Aicale1*, D. Tarantino1 and N. Maffulli1,2 Abstract Background: The absence of a single, identifiable traumatic cause has been traditionally used as a definition for a causative factor of overuse injury. Excessive loading, insufficient recovery, and underpreparedness can increase injury risk by exposing athletes to relatively large changes in load. The musculoskeletal system, if subjected to excessive stress, can suffer from various types of overuse injuries which may affect the bone, muscles, tendons, and ligaments. Methods: We performed a search (up to March 2018) in the PubMed and Scopus electronic databases to identify the available scientific articles about the pathophysiology and the incidence of overuse sport injuries. For the purposes of our review, we used several combinations of the following keywords: overuse, injury, tendon, tendinopathy, stress fracture, stress reaction, and juvenile osteochondritis dissecans. Results: Overuse tendinopathy induces in the tendon pain and swelling with associated decreased tolerance to exercise and various types of tendon degeneration. Poor training technique and a variety of risk factors may predispose athletes to stress reactions that may be interpreted as possible precursors of stress fractures. A frequent cause of pain in adolescents is juvenile osteochondritis dissecans (JOCD), which is characterized by delamination and localized necrosis of the subchondral bone, with or without the involvement of articular cartilage. The purpose of this compressive review is to give an overview of overuse injuries in sport by describing the theoretical foundations of these conditions that may predispose to the development of tendinopathy, stress fractures, stress reactions, and juvenile osteochondritis dissecans and the implication that these pathologies may have in their management.
    [Show full text]
  • Vitamin D and Bone Health
    1150 17th Street NW Suite 850 Washington, D.C. 200361 Bone Basics 1 (800) 231-4222 TEL ©National Osteoporosis Foundation 2013 1 (202) 223-2237 FAX www.nof.org Vitamin D and Bone Health Vitamin D plays an important role in protecting your bones. It may also help prevent other conditions including certain cancers. Your body requires vitamin D to absorb calcium. Children need vitamin D to build strong bones, and adults need it to keep bones strong and healthy. When people do not get enough vitamin D, they can lose bone. Studies show that people with low levels of vitamin D have lower bone density or bone mass. They are also more likely to break bones when they are older. Severe vitamin D deficiency is rare in the United States. It can cause a disease known as osteomalacia where the bones become soft. In children, this is known as rickets. These are both different conditions from osteoporosis. NOF Recommendations for Vitamin D The National Osteoporosis Foundation (NOF) recommends that adults under age 50 get 400-800 International Units (IU) of vitamin D every day, and that adults age 50 and older get 800-1,000 IU of vitamin D every day. Some people need more vitamin D. There are two types of vitamin D supplements. They are vitamin D2 and vitamin D3. Previous research suggested that vitamin D3 was a better choice than vitamin D2. However, more recent studies show that vitamin D3 and vitamin D2 are fairly equal for bone health. Vitamin D3 is also called cholecalciferol. Vitamin D2 is also called ergocalciferol.
    [Show full text]